Novo Nordisk Inc. Et Al V. Rio Biopharmaceuticals, Inc. Et Al
A lawsuit has been filed by Novo Nordisk Inc. and Novo Nordisk A/S against several companies, including Rio Biopharmaceuticals, Inc., EMS S/A, Sun Pharmaceutical Industries Ltd., SUN PHARMACEUTICAL INDUSTRIES INC., Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., ZYDUS LIFESCIENCES LIMITED, DR. REDDY'S LABORATORIES LTD., Dr. Reddy's Laboratories Inc., and ALVOGEN, INC. The lawsuit alleges that these companies have infringed on Novo Nordisk's patents under the United States Code, Title 35, by submitting an Abbreviated New Drug Application to the United States Food and Drug Administration seeking approval to market a generic version of Novo Nordisk's pharmaceutical product Ozempic® before the expiration of United States Patent Nos. 8,129,343, 9,132,239, 9,457,154, 9,687,611, and 10,335,462, which cover Ozempic® and/or its use. The plaintiffs are seeking damages and an injunction to prevent the defendants from selling the generic version of Ozempic®.
Read Next